Protagonist Therapeutics, Inc. (PTGX)

24.72 -0.98 (-3.81%) As of 01:18PM EDT. Market open.

Protagonist Therapeutics, Inc.

7707 Gateway Boulevard
Suite 140
Newark, CA 94560-1160
United States
510 474 0170
https://www.protagonist-inc.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 112

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Dinesh V. Patel Ph.D.	CEO, President, Secretary & Director	883.46k	N/A	1957
Dr. Suneel K. Gupta Ph.D.	Chief Development Officer	640.89k	N/A	1959
Dr. Mark Smythe Ph.D.	Founder & VP Technology	N/A	N/A	1965
Mr. Asif Ali	Executive VP & Chief Financial Officer	N/A	N/A	1974
Mr. Mohammad Masjedizadeh Ph.D.	Executive VP & Chief Technical Officer	N/A	N/A	N/A
Mr. Matthew M. Gosling	Executive VP & General Counsel	N/A	N/A	1971
Ms. Carena Spivey	Head of HR & Senior VP of Human Resources	N/A	N/A	N/A
Dr. Ashok Bhandari Ph.D.	Executive VP & Chief Drug Discovery and Preclinical Development Officer	N/A	N/A	1964
Mr. Carter J. King	Executive Vice President of Business Development	N/A	N/A	1971
Ms. Abha Bommireddi	Executive Vice President of Portfolio & Program Management	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Corporate governance

Protagonist Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.